Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Berger

Showing results (741-750 of 774) with videos related to

Pageof 78
Sort By:
Circulation|February 3, 2005
Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart AssociationAlexandra J Lansky, Judith S Hochman, Patricia A Ward, et al.
JAMA|November 14, 2015
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial, Jeffrey G Gross, Adam R Glassman, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trialG B John Mancini, Eric R Bates, David J Maron, et al.
The American Journal of Cardiology|March 5, 2004
Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study)David E Kandzari, Alan Chu, Bruce R Brodie, et al.
The Journal of Invasive Cardiology|June 8, 2011
Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trialTesfaldet T Michael, Abdul-rahman R Abdel-karim, Aristotelis Papayannis, et al.
Circulation|May 31, 2001
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter studyS R Steinhubl, J D Talley, G A Braden, et al.
Archives of Internal Medicine|January 16, 2008
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapyGustavo B F Oliveira, Eric M Crespo, Richard C Becker, et al.
Lancet (London, England)|September 6, 2013
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational studyRoxana Mehran, Usman Baber, Philippe Gabriel Steg, et al.
Circulation|November 16, 2017
Impact of Regionalization of ST-Segment-Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Services-Transported Patients Presenting to Hospitals With Percutaneous Coronary Intervention: Mission: Lifeline Accelerator-2James G Jollis, Hussein R Al-Khalidi, Mayme L Roettig, et al.
JAMA|March 17, 2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trialMatthew J Price, Peter B Berger, Paul S Teirstein, et al.
Pageof 78

Showing results (741-750 of 774) with videos related to

Sort By:
Pageof 78
Circulation|February 3, 2005
Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart AssociationAlexandra J Lansky, Judith S Hochman, Patricia A Ward, et al.
JAMA|November 14, 2015
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial, Jeffrey G Gross, Adam R Glassman, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trialG B John Mancini, Eric R Bates, David J Maron, et al.
The American Journal of Cardiology|March 5, 2004
Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study)David E Kandzari, Alan Chu, Bruce R Brodie, et al.
The Journal of Invasive Cardiology|June 8, 2011
Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trialTesfaldet T Michael, Abdul-rahman R Abdel-karim, Aristotelis Papayannis, et al.
Circulation|May 31, 2001
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter studyS R Steinhubl, J D Talley, G A Braden, et al.
Archives of Internal Medicine|January 16, 2008
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapyGustavo B F Oliveira, Eric M Crespo, Richard C Becker, et al.
Lancet (London, England)|September 6, 2013
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational studyRoxana Mehran, Usman Baber, Philippe Gabriel Steg, et al.
Circulation|November 16, 2017
Impact of Regionalization of ST-Segment-Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Services-Transported Patients Presenting to Hospitals With Percutaneous Coronary Intervention: Mission: Lifeline Accelerator-2James G Jollis, Hussein R Al-Khalidi, Mayme L Roettig, et al.
JAMA|March 17, 2011
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trialMatthew J Price, Peter B Berger, Paul S Teirstein, et al.
Pageof 78